SciSparc Ltd., o se kamupani faʻapitoa, falemaʻi faʻataʻitaʻiga o loʻo taulaʻi i le atinaʻeina o togafitiga e togafitia ai faʻafitauli o le fatugalemu o le tino, i aso nei na faʻasalalau ai le faʻatulagaina o se pisinisi faʻatasi ("JV") e taulaʻi i le mauaina ma le atinaʻeina o mea e mafai. fualaau mo kanesa ma isi tulaga e lamatia ai le ola. I lalo o tuutuuga a le JV, ina ia faʻalauiloa lenei faʻamoemoe, SciSparc o le a faʻatuina se kamupani fou suʻesuʻe vailaʻau, MitoCareX Bio Ltd., o se faʻalapotopotoga a Isaraelu ("MitoCareX Bio").
O le a taulaʻi le JV i le suʻesuʻeina o vaʻavaʻa mitochondrial, felauaiga polotini e taua tele mo le faʻaogaina o sela. Ona o le taua tele o le sao o le ave o le mitochondrial i le felauaiga o metabolites talafeagai mo le gaioiina o sela i totonu o le mitochondrial membranes, ua talitonu le Kamupani o tulaga eseese e lamatia ai le ola, e pei o kanesa ma faamaʻi mitochondrial e le masani ai, e mafai ona togafitia e ala i le faatonutonuina o le galuega a ave mitochondrial. I totonu o tagata, o le aiga o le mitochondrial carrier (Solute Carrier Family 25, SLC25) e aofia ai le 53 sui ma o le tele o le solute transporter aiga.
"O se avanoa fiafia lenei e ono faʻalautele atili ai le matou paipa i le tele o faʻailoga fou e faʻatatau i manaʻoga faafomaʻi tetele e leʻi ausia," o le tala lea a Oz Adler, Ofisa Sili o Pulega ma Ofisa Sili o Tupe a SciSparc. "O loʻo faʻamoemoe le MitoCareX Bio e faʻaaogaina tomai faʻapitoa e suʻesuʻe ai vailaʻau, faʻaaogaina le tele o suʻesuʻega suʻesuʻega ma le poto faʻapitoa i totonu o le fanua, e suʻe ai ma mafai ona atiaʻe se paipa e ono aofia ai ni molelaʻau laiti e faʻatatau i polotini o tului i tulaga eseese e lamatia ai le ola."
Ina ia fausia le JV, SciSparc o le a faʻatuina se kamupani fou suʻesuʻe vailaʻau, MitoCareX Bio Ltd. (“MitoCareX Bio”). Fa'avae i luga o fa'ailoga mata'utia, SciSparc o le a fa'aagaga e o'o atu i le $1.7 miliona, mo le o'o atu i le 50.01 pasene le umiaina, i le MitoCareX Bio i le isi lua tausaga ma e tusa ai ma le tele o fa'ailoga ua malilie i ai i totonu o le maliliega. O su'esu'ega fou a le MitoCareX Bio o le a fa'avaeina i luga o fa'ata'ita'iga fa'amaonia manuia na faia i Peretania. O Polofesa Ciro Leonardo Pierri (Iunivesite o Bari, Italia), o se tagata tomai faapitoa i le lalolagi atoa i le tulaga o le mitochondrial carrier proteins, ua faailoa atu i le Kamupani o loo ia faamoemoe e lagolago le polokalame o se faufautua i le Kamupani.
OA MEA E AVEA MAI LENEI TUSI:
- , a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture (“JV”) to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions.
- Professor Ciro Leonardo Pierri (University of Bari, Italy), a global expert in the field of mitochondrial carrier proteins, has indicated to the Company that he intends to support the program as a consultant to the Company.
- “MitoCareX Bio intends to employ computationally-based drug discovery capabilities, leveraging vast research experience and specific knowledge in the field, to discover and potentially develop a pipeline that may include small molecules targeting the proteins of interest in various life-threatening conditions.
